Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer:. A real-world data, non-inferiority analysis

Simple item page
dc.contributor.authorVisa, Laura
dc.contributor.authorJimenez-Fonseca, Paula
dc.contributor.authorAsensio Martinez, Elena
dc.contributor.authorHernandez, Raquel
dc.contributor.authorCustodio, Ana
dc.contributor.authorGarrido, Manuel
dc.contributor.authorViudez, Antonio
dc.contributor.authorBuxo, Elvira
dc.contributor.authorEchavarria, Ignacio
dc.contributor.authorMaria Cano, Juana
dc.contributor.authorMacias, Ismael
dc.contributor.authorMangas, Montserrat
dc.contributor.authorMartinez de Castro, Eva
dc.contributor.authorGarcia, Teresa
dc.contributor.authorAlvarez Mancenido, Felipe
dc.contributor.authorFernandez Montes, Ana
dc.contributor.authorAzkarate, Aitor
dc.contributor.authorLongo, Federico
dc.contributor.authorDiaz Serrano, Asuncion
dc.contributor.authorLopez, Carlos
dc.contributor.authorHurtado, Alicia
dc.contributor.authorCerda, Paula
dc.contributor.authorSerrano, Raquel
dc.contributor.authorGil-Negrete, Aitziber
dc.contributor.authorMartin Carnicero, Alfonso
dc.contributor.authorPimentel, Paola
dc.contributor.authorRamchandani, Avinash
dc.contributor.authorCarmona-Bayonas, Alberto
dc.date.accessioned2025-01-23T21:22:43Z
dc.date.available2025-01-23T21:22:43Z
dc.date.issued2018
dc.description.abstractObjective: Advanced gastric cancer (AGC) is a common neoplasm in older adults. Nevertheless, there are few specific management data in the literature. The aim of this study was to assess non-inferiority of survival and efficacy-related outcomes of chemotherapy used in older vs non-older patients with ACC
dc.description.abstractMaterials and Methods: We recruited 1485 patients from the AGAMENON registry of AGC treated with polychemotherapy between 2008-2017. A statistical analysis was conducted to prove non-inferiority for overall survival (OS) associated with the use of chemotherapy schedules in individuals >= 70 vs.<70 years. The fixed margin method was used (hazard ratio [HR]<1.176) that corresponds to conserving at least 85% efficacy.
dc.description.abstractResults: 33% (n = 489) of the cases analyzed were. >= 70 years. Two-agent chemotherapie's and combinations with oxaliplatin (48% vs. 29%) were used more often in the older patients, as were modified schedules and/or lower doses. Toxicity grade 3-4 was comparable in both groups, although when looking at any grade, there were more episodes of enteritis, renal toxicity, and fatigue in older patients. In addition, toxicity was a frequent cause for discontinuing treatment in older patients. The response rate was similar in both groups. After adjusting for confounding factors, the non-inferiority of OS associated with schedules administered to the older vs. younger subjects was confirmed: HR 1.02 (90% CI, 0.91-1.14), P (non inferiority) = 0.018, as well as progression-free survival: HR 0.97 (90% CI, 0.87-1.08), P( non-inferiority) = 0.001.
dc.description.abstractConclusion: In this AGC registry, the use of chemotherapy with schedules adapted to patients 70 years provided efficacy that was not inferior to that seen in younger cases, with comparable adverse effects. (C) 2017 Elsevier Ltd. All rights reserved.
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.jgo.2017.11.008
dc.identifier.eissn1879-4076
dc.identifier.issn1879-4068
dc.identifier.urihttps://doi.org/10.1016/j.jgo.2017.11.008
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/101262
dc.identifier.wosidWOS:000431935100012
dc.issue.numero3
dc.language.isoen
dc.pagina.final264
dc.pagina.inicio254
dc.revistaJournal of geriatric oncology
dc.rightsacceso restringido
dc.subjectOlder
dc.subjectChemotherapy
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEfficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer:. A real-world data, non-inferiority analysis
dc.typeartículo
dc.volumen9
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas